The trading price of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) floating lower at last check on Monday, Feb 22, closing at $6.9, -32.17% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it has been fluctuating between $4.5900 and $5.0400. The company’s P/E ratio in the trailing 12-month period was 0, while its 5Y monthly beta was 0.22. In examining the 52-week price action we see that the stock hit a 52-week high of $17.95 and a 52-week low of $3.8. Over the past month, the stock has gained 32.69% in value.
Brainstorm Cell Therapeutics Inc., whose market valuation is $235.77 Million at the time of this writing, is expected to release its quarterly earnings report May 05, 2021- May 10, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.26 per share this quarter, however they have predicted annual earnings per share of -$1.01 for 2021 and -$0.49 for 2022. It means analysts are expecting annual earnings per share growth of -0.06% this year and -0.51% next year.
On the technical side, indicators suggest BCLI has a 50% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
An evaluation of the daily trading volume of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) indicates that the 3-month average is 1.15 Million. However, this figure has increased over the past 10 days to an average of 565.06 Million.
Currently, records show that 35.72 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 19.78% of outstanding shares, whereas institutions hold 22.78%. The stats also highlight that short interest as of January 28, 2021, stood at 4.66 Million shares, resulting in a short ratio of 4.23 at that time. From this, we can conclude that short interest is 13.27% of the company’s total outstanding shares. It is noteworthy that short shares in January were down slightly from the previous month’s figure, which was 5.4 Million. However, since the stock’s price has seen +52.49% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.